The role of community pharmacies in mental health support and medication management

1. INTRODUCTION

Mental health care has increasingly gained prominence as a critical public health issue, affecting millions of individuals worldwide. The World Health Organization (WHO) estimates that approximately one in four people will be affected by a mental or neurological disorder at some point in their lives. Depression, anxiety, bipolar disorder, and schizophrenia are among the most prevalent mental health conditions, placing a significant burden on healthcare systems globally. As the demand for mental health services grows, the need for accessible, affordable, and comprehensive care becomes even more pressing. In this context, community pharmacies have emerged as vital players in the provision of mental health support and medication management. Traditionally, community pharmacies have been known for their role in dispensing medications and providing patients with essential advice on the proper use of drugs. However, their role in healthcare has evolved significantly over the years, particularly in mental health care. With their accessibility, community-centered approach, and expertise in pharmacology, community pharmacists are uniquely positioned to contribute to mental health support. In many cases, they serve as the first point of contact for individuals seeking help with mental health concerns, offering services that go beyond simple medication dispensing to encompass patient education, counseling, and medication therapy management (MTM) [1], [2], [3].

One of the primary advantages of community pharmacies in mental health care is their accessibility. Unlike specialized mental health facilities, community pharmacies are widespread and often located in neighborhoods that may lack mental health services. This allows pharmacists to engage with patients who might not otherwise seek mental health care due to stigma, lack of awareness, or limited access to mental health professionals. By integrating mental health support into routine pharmacy services, community pharmacists can help bridge the gap between patients and the healthcare system, offering timely interventions that can prevent mental health conditions from worsening. Another key benefit of community pharmacies is their potential to reduce the stigma associated with mental health conditions. Mental illness remains highly stigmatized in many societies, preventing individuals from seeking help or adhering to prescribed treatments. Pharmacists, by offering non-judgmental, patient-centered care, can create a safe environment for individuals to discuss their mental health concerns. Through frequent interactions with patients, pharmacists can foster trusting relationships that enable patients to feel more comfortable sharing sensitive information about their mental health. This open communication can lead to early identification of mental health issues, allowing for timely referrals to mental health specialists or appropriate treatment interventions [4], [5], [6].

Medication management is a cornerstone of community pharmacies' contribution to mental health care. Many individuals with mental health conditions are prescribed psychotropic medications, such as antidepressants, antipsychotics, and mood stabilizers. While these medications can be highly effective, they often require careful monitoring due to potential side effects, interactions with other drugs, and the need for dose adjustments over time. Community pharmacists play a crucial role in ensuring that patients adhere to their medication regimens, addressing any concerns they may have about side effects, and providing information on how to manage potential challenges associated with mental health medications. Pharmacists are also well-equipped to identify medication-related problems, such as suboptimal dosing, drug interactions, or adherence issues, which can affect treatment outcomes. For example, many patients with depression or anxiety may discontinue their medication prematurely due to the delayed onset of therapeutic effects, or they may experience intolerable side effects that lead to non-adherence. Community pharmacists can intervene in these situations by providing patient education, addressing concerns, and suggesting alternative therapies in collaboration with prescribing clinicians [6], [7]. Their role in medication reconciliation, where they review all medications, a patient is taking, ensures that psychotropic drugs are used safely and effectively, minimizing the risk of adverse drug reactions (ADRs) or interactions with other treatments. Moreover, community pharmacies are becoming increasingly involved in mental health screenings and assessments. Through the use of standardized screening tools for conditions such as depression, anxiety, and substance abuse, pharmacists can identify patients who may benefit from further evaluation by mental health professionals. These screenings are often conducted discreetly and with minimal patient discomfort, providing an accessible way for individuals to seek help for mental health concerns without needing to visit a specialized clinic. Pharmacists can then facilitate referrals to appropriate healthcare providers, ensuring a seamless transition to specialized care when needed. The integration of mental health services into community pharmacies is not without challenges. Pharmacists may face barriers such as time constraints, lack of specialized mental health training, and limited resources for providing comprehensive mental health care. However, ongoing professional development and the use of technology, such as telepharmacy and electronic health records, are helping pharmacists overcome these obstacles. Collaborative care models, where pharmacists work closely with other healthcare professionals, such as physicians, nurses, and mental health specialists, are also being adopted to enhance the quality of care provided to patients with mental health conditions [7], [8], [9], [10].

2. RELATED WORK

Community pharmacies have emerged as crucial contributors to mental health support and medication management due to their accessibility and regular interaction with patients. Traditionally known for dispensing medications, community pharmacies have expanded their role to include providing mental health services. This shift reflects growing recognition of the importance of integrating mental health care into everyday healthcare settings. Community pharmacists are well-positioned to address the unmet needs of individuals suffering from mental health disorders, particularly those who may not have easy access to specialized care. One major area where community pharmacies have contributed significantly is medication adherence in mental health care. Mental health disorders often require long-term pharmacotherapy, and non-adherence to prescribed treatment is a common challenge. Pharmacists play a key role in reinforcing the importance of medication adherence through patient counseling, providing reminders, and helping manage side effects [11]. Studies suggest that pharmacist interventions, including regular consultations and follow-ups, significantly improve adherence rates in patients with mental health conditions, leading to better treatment outcomes. By providing personalized care and addressing individual concerns, community pharmacists can build trust and encourage patients to stick with their prescribed treatments. Another key area is the management of psychotropic medications, which are often complex and require careful monitoring. Psychotropic drugs, used to treat conditions such as depression, anxiety, and schizophrenia, can have significant side effects and require ongoing adjustments. Community pharmacists assist in monitoring these medications by identifying potential drug interactions, adjusting dosages, and ensuring that patients understand their treatment regimens. They serve as a critical link between patients and healthcare providers, ensuring that medication therapies are both safe and effective. By engaging in continuous monitoring, pharmacists help prevent adverse drug reactions and enhance the therapeutic efficacy of mental health medications [12], [13], [14], [15].

Community pharmacies also play an important role in early detection of mental health issues. Patients may initially approach pharmacists with physical symptoms that mask underlying mental health problems, such as insomnia, fatigue, or gastrointestinal complaints. Pharmacists, with their frequent contact with patients, can identify these symptoms and initiate conversations about mental health. By screening for depression, anxiety, and other mental health conditions, community pharmacists can facilitate early intervention and direct patients to appropriate mental health services. Early detection is particularly important because it allows for timely treatment, which can prevent the progression of mental health disorders. In addition to direct patient care, community pharmacists contribute to public mental health education. They engage in activities aimed at reducing stigma around mental health disorders, encouraging patients to seek help, and providing educational resources. Community pharmacies often serve as accessible centers where individuals can get information about mental health services and the available treatments. By fostering an open dialogue, pharmacists help destigmatize mental health conditions, which is essential for encouraging people to seek timely treatment. The introduction of digital health technologies in community pharmacies has further enhanced their role in mental health care. With telemedicine becoming more prevalent, pharmacists are now able to offer virtual consultations and support services. This digital integration allows pharmacists to reach a broader population, particularly those in remote areas who may have limited access to mental health services. Additionally, digital tools help pharmacists monitor patient adherence, manage side effects, and provide timely interventions when needed. These innovations have expanded the capacity of community pharmacies to deliver mental health care beyond traditional in-person visits [16], [17].

Pharmacists are also instrumental in addressing the growing public health challenge of mental health during crises, such as the COVID-19 pandemic. During the pandemic, community pharmacies remained one of the few accessible healthcare settings, providing essential mental health support when other services were disrupted. Pharmacists adapted to the increased demand for mental health services by offering counseling, ensuring the continuity of medication supplies, and addressing the mental health impacts of isolation, fear, and stress. This experience highlighted the resilience and adaptability of community pharmacies in responding to mental health needs during emergencies. However, despite their expanding role, community pharmacies face challenges in mental health care provision. Barriers include limited time for in-depth consultations due to high workloads, lack of specialized mental health training, and inadequate reimbursement for mental health services. Addressing these challenges requires ongoing professional development, advocacy for policy changes that recognize the role of pharmacists in mental health care, and improvements in the healthcare system to support the integration of pharmacists into multidisciplinary mental health teams [18], [19], [20].

3. METHODOLOGY

This review follows a structured approach to examine the role of community pharmacies in mental health support and medication management. The methodology consisted of several stages: literature search, selection, analysis, and synthesis of findings. The first step involved an extensive search of electronic databases such as PubMed, Google Scholar, and Scopus. The search focused on identifying peer-reviewed articles, reports, and relevant publications, using keywords like “community pharmacies,” “mental health support,” “medication management,” “pharmacist interventions,” and “psychotropic medication.” To ensure the inclusion of up-to-date insights, the search was limited to articles published within the last decade. Following the search, articles were screened based on their relevance to the topic. The selection criteria required studies to focus specifically on the role of community pharmacists in mental health care, addressing aspects of medication management or including qualitative or quantitative data on pharmacist interventions. Articles that did not directly address mental health care in community pharmacies or lacked clear empirical evidence were excluded from the review. Once the relevant studies were identified, data extraction and analysis were conducted.

The analysis centered on pharmacist interventions, their impact on patient outcomes, and the challenges faced by community pharmacies in providing mental health care. Common themes identified across the literature included medication adherence, patient counseling, and mental health screening. The findings from these studies were then synthesized to offer a comprehensive overview of community pharmacy involvement in mental health care. Key trends, successful interventions, and existing gaps in the field were highlighted. This methodological approach ensures that the review provides valuable insights into current practices and suggests potential future directions for improving mental health support through community pharmacies.

4. RESULTS AND DISCUSSION

The review of literature highlighted several significant findings regarding the role of community pharmacies in mental health support and medication management. These findings underscore the increasing recognition of community pharmacists as accessible healthcare providers, especially in mental health care, where access to specialists may be limited. One of the most prominent findings is the positive impact of pharmacist-led interventions on medication adherence in patients with mental health conditions. Many studies showed that patients benefited from pharmacist counseling and medication management services. The support provided by community pharmacists improved adherence to psychotropic medications, which in turn led to better mental health outcomes. Pharmacists' involvement in monitoring side effects, adjusting dosages in collaboration with prescribing physicians, and providing timely refills contributed significantly to patients' medication adherence. In some cases, pharmacists were also involved in identifying potential medication-related problems, reducing the likelihood of adverse drug reactions, and promoting patient safety [21], [22].

Another key finding is the expanding role of pharmacists in mental health screening. As community pharmacies are often easily accessible and frequented by a diverse patient population, pharmacists are increasingly engaged in identifying patients with undiagnosed mental health conditions, such as depression or anxiety. Screening tools and questionnaires administered by pharmacists provided an early identification of mental health concerns, allowing for timely referrals to specialists. This proactive approach is particularly valuable in underserved areas, where access to mental health professionals may be scarce. However, despite these positive contributions, challenges remain in fully integrating mental health services into community pharmacies [23], [24], [25]. Limited training in mental health for pharmacists, time constraints, and the need for stronger collaboration with mental health professionals are notable barriers. Additionally, the lack of formal recognition of pharmacists as mental health care providers in some regions hampers the expansion of their role. Financial incentives and reimbursement models for pharmacists providing mental health services are also underdeveloped, limiting the sustainability of such services. The discussion of these findings emphasizes that while community pharmacists have demonstrated their potential to positively impact mental health care, structural and educational improvements are necessary to enhance their role [26], [27], [28], [29], [30]. Expanding mental health training for pharmacists would allow them to be more effective in managing psychotropic medications and conducting mental health screenings. Furthermore, establishing stronger collaborations between pharmacists and mental health professionals would create a more integrated care approach, ensuring patients receive comprehensive support. Policymakers and healthcare organizations need to recognize the value of community pharmacists in mental health care by providing appropriate resources, training, and reimbursement models [31], [32], [33], [34], [35], [36], [37].

5. CONCLUSION

Community pharmacies are uniquely positioned to address critical gaps in mental health support and medication management. As accessible and trusted healthcare providers, community pharmacists have demonstrated their ability to improve medication adherence among patients with mental health conditions, thus contributing to better therapeutic outcomes. Their involvement in monitoring medication side effects, adjusting dosages in collaboration with prescribing doctors, and providing patient counseling ensures a more personalized and consistent approach to mental health care.In addition to medication management, community pharmacists have emerged as key players in early mental health screening and referral services. With their widespread presence and regular interactions with patients, pharmacists are well-placed to identify early signs of mental health disorders such as depression and anxiety, particularly in populations that might not have easy access to mental health professionals. Through the use of standardized screening tools, pharmacists can facilitate early intervention, which is essential for improved patient outcomes. However, the role of community pharmacists in mental health care is not without challenges. Barriers such as limited mental health training, time constraints, and the lack of formal recognition and reimbursement for mental health services hinder the full integration of these services into pharmacy practice. Addressing these challenges through targeted training programs, better collaboration with mental health professionals, and the development of appropriate financial incentives is crucial for maximizing the impact of pharmacists in this domain.

Community pharmacies have the potential to be a valuable resource in the broader mental health care system. With the right support, training, and policy changes, community pharmacists can play a more expansive and effective role in mental health support and medication management, ultimately contributing to a more accessible and integrated healthcare system

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

C: Conceptualization; M: Methodology; So: Software; Va: Validation; Fo: Formal analysis; I: Investigation; R: Resources; D: Data curation; O: Writing – original draft; E: Writing – review & editing; Vi: Visualization; Su: Supervision; P: Project administration; Fu: Funding acquisition.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

Not Applicable.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. [1] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and infertility: an update', International journal of adolescent medicine and health, vol. 34, pp. 1-9, July 2021. doi.org/10.1515/ijamh-2021-0073
2. [2] R. J. Lihite et al., 'A study on adverse drug reactions in a tertiary care hospital of Northeast India', Alexandria journal of medicine, vol. 53, pp. 151-156, July 2017. doi.org/10.1016/j.ajme.2016.05.007
3. [3] M. Zehravi and M. Maqbool, 'Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 339-345, June 2021. doi.org/10.1515/ijamh-2021-0058
4. [4] M. Maqbool, F. Bekele, and G. Fekadu, 'Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy', pp. 15-24, Jan. 2022. doi.org/10.2147/BCTT.S348060
5. [5] S. Rasool and M. Maqbool, 'An overview about Hedychiumspicatum: a review', vol. 9, pp. 476-480, Feb. 2019. doi.org/10.22270/jddt.v9i1-s.2429
6. [6] M. Zehravi and M. Maqbool, 'Depression and anxiety in women with polycystic ovarian syndrome: a literature survey', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 367-373, Aug. 2021. doi.org/10.1515/ijamh-2021-0092
7. [7] M. Maqbool, I. Gani, and M. A. Dar, 'Anti-diabetic effects of some medicinal plants in experimental animals: a review', Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 1, pp. 66-69, Feb. 2019. doi.org/10.22270/ajprd.v7i1.469
8. [8] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health', vol. 33, pp. 333-337, Apr. 2021. doi.org/10.1515/ijamh-2021-0031
9. [9] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, 'Polycystic ovary syndrome, a modern epidemic: an overview', Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019. doi.org/10.22270/jddt.v9i3.2661
10. [10] M. Maqbool et al., 'An up to date on clinical prospects and management of osteoarthritis', Annals of Medicine and Surgery, vol. 72, Dec. 2021. doi.org/10.1016/j.amsu.2021.103077
11. [11] A. Majeed, R. Bashir, S. Farooq, and M. Maqbool, 'Preparation, characterization and applications of nanoemulsions: An insight', Journal of Drug Delivery and Therapeutics, vol. 9, no. 2, pp. 520-527, Mar. 2019. doi.org/10.22270/jddt.v9i2.2410
12. [12] M. Zehravi and M. Maqbool, 'Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review', Open Health, vol. 3, pp. 60-65, May 2022. doi.org/10.1515/openhe-2022-0008
13. [13] R. Maqbool, M. Maqbool, and M. Zehravi, 'Menstrual distress in females of reproductive age: a literature review', International journal of adolescent medicine and health, vol. 34, pp. 11-17, July 2021. doi.org/10.1515/ijamh-2021-0081
14. [14] I. Ara, M. Maqbool, G. Fekadu, T. A. Hajam, and M. A. Dar, 'Pharmaceutical significance of Nigella sativa L., a wonder herb', Journal of Applied Pharmaceutical Sciences and Research, vol. 3, no. 4, pp. 4-13, 2020. doi.org/10.31069/japsr.v3i4.2
15. [15] M. Maqbool, N. Nasir, and S. Mustafa, 'Polycystic in ovarian syndrome and its various treatment strategies', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 5, no. 9, pp. 8470-8478, Sept. 2018.
16. [16] M. Maqbool, M. Zehravi, and R. Maqbool, 'Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital', India. CELLMED, vol. 11, no. 2, pp. 8-9, 2021.
17. [17] I. Ara, M. Maqbool, B. Bukhari, and A. N. Hajam, 'Present status, standardization and safety issues with herbal drugs', International Journal of Research in Pharmaceutical Sciences and Technology, vol. 1, no. 3, pp. 95-101, May 2020. doi.org/10.33974/ijrpst.v1i3.169
18. [18] I. Ara, M. Maqbool, and I. Gani, 'Reproductive Health of Women: implications and attributes', International Journal of Current Research in Physiology and Pharmacology, pp. 8-18, Nov. 2022.
19. [19] M. Zehravi, R. Maqbool, and M. Maqbool, 'To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India', Journal of Pharmaceutical Research International, vol. 33, no. 31A, pp. 135-140, June 2021. doi.org/10.9734/jpri/2021/v33i31A31673
20. [20] M. Maqbool, S. Javed, and A. A. Bajwa, 'Assessment OF pain management IN postoperative cases using different scales and questionnaires', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 6, no. 1, pp. 983-987, Jan. 2019.
21. [21] I. Ara, M. Maqbool, and M. Zehravi, 'Psychic consequences of infertility on couples: A short commentary', Open Health, vol. 3, pp. 114-119, Jan. 2022. doi.org/10.1515/openhe-2022-0022
22. [22] R. Bashir, M. Maqbool, and A. I. Zehravi, 'An In sight into Novel Drug Delivery System', In Situ Gels. CELLMED, vol. 11, no. 1, pp. 6-7, 2021.
23. [23] M. Zehravi and M. Maqbool, 'Teenage menstrual dysfunction: an overview', International Journal of Adolescent Medicine and Health, vol. 35, no. 1, pp. 15-19, Sept. 2022. doi.org/10.1515/ijamh-2022-0018
24. [24] I. Ara, M. Zehravi, M. Maqbool, and I. Gani, 'A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries', Journal of Pharmaceutical Research & Reports, no. 3, 2022.
25. [25] M. Maqbool, W. Shabbir, and S. Aamir, 'Adverse events of blood transfusion and blood safety in clinical practice', Indo American Journal Of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.
26. [26] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.
27. [27] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
28. [28] M. Maqbool, U. Ikram, and A. Anwar, 'Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders', Indo American Journal Of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8060-8065, Aug. 2018.
29. [29] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
30. [30] M. Zehravi and M. Maqbool, 'An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India', The Indian Journal of Nutrition and Dietetics, pp. 408-418, July 2021. doi.org/10.21048/IJND.2021.58.3.27285
31. [31] M. Maqbool and M. Zehravi, 'Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation', vol. 1, Dec. 2021. doi.org/10.5812/ipmn.117170
32. [32] M. Maqbool and A. I. Gani, 'The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age', International Journal of Current Research in Physiology and Pharmacology, pp. 19-31, Nov. 2022.
33. [33] M. Maqbool and I. Gani, 'Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review', Journal of Pharmacy Practice and Community Medicine, vol. 4, no. 4, 2018. doi.org/10.5530/jppcm.2018.4.46
34. [34] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
35. [35] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
36. [36] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.
37. [37] M. Maqbool, W. Shabbir, and S. Aamir, 'Adverse events of blood transfusion and blood safety in clinical practice', Indo American Journal Of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.